← Eichor
Study identifier: NCT07032727 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

Condition: Targeted Therapy · IDH1-Mutated Malignancies · Mutations  ·  Sponsor: M.D. Anderson Cancer Center

PhasePhase 2
Planned participants68
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

To learn about the safety and tolerability of study drug combinations in patients with relapsed/refractory, IDH1-mutated myeloid malignancies with a co-signaling mutation.

This description comes directly from the study's public registry record.

Talk to the study team

Courtney DiNardo, MD  ·  713-794-1141  ·  cdinardo@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (1)

MD Anderson Cancer CenterHouston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07032727